实体肿瘤分子靶向治疗与免疫靶向治疗疗效评价指标的研究进展

Novel response evaluation indicators of anticancer immunotherapy and targeted therapy in solid tumors

肿瘤靶向治疗和免疫治疗常有非常规反应模式,这需要更加客观和精准的评价指标。新的肿瘤疗效评价指标有肿瘤缓解深度、肿瘤缓解时间、临床获益率、早期终点指标和其它替代指标,这些评价指标尝试寻找最佳时间点和精准量化的结合,未来将可能替代常规的RECIST标准。

Patients with solid tumors can have unusual patterns of response to anticancer immunotherapy and targeted therapy,necessitating the adoption of novel response evaluation indicators.Novel response evaluation indicators include the depth of response,duration of response,clinical benefit rate,early end point and surrogate endpoints.These response indicators try to combine best time point with precision number,and will replace the traditional response evaluation criteria.